PMID- 33686197
OWN - NLM
STAT- MEDLINE
DCOM- 20211230
LR  - 20221018
IS  - 1476-5551 (Electronic)
IS  - 0887-6924 (Linking)
VI  - 35
IP  - 11
DP  - 2021 Nov
TI  - A prognostic survival model based on metabolism-related gene expression in plasma 
      cell myeloma.
PG  - 3212-3222
LID - 10.1038/s41375-021-01206-4 [doi]
AB  - Accurate survival prediction of persons with plasma cell myeloma (PCM) is 
      challenging. We interrogated clinical and laboratory co-variates and RNA matrices 
      of 1040 subjects with PCM from public datasets in the Gene Expression Omnibus 
      database in training (N = 1) and validation (N = 2) datasets. Genes regulating 
      plasma cell metabolism correlated with survival were identified and seven used to 
      build a metabolic risk score using Lasso Cox regression analyses. The score had 
      robust predictive performance with 5-year survival area under the curve (AUCs): 
      0.71 (95% confidence interval, 0.65, 0.76), 0.88 (0.67, 1.00) and 0.64 (0.57, 
      0.70). Subjects in the high-risk training cohort (score > median) had worse 
      5-year survival compared with those in the low-risk cohort (62% [55, 68%] vs. 85% 
      [80, 90%]; p < 0.001). This was also so for the validation cohorts. A nomogram 
      combining metabolic risk score with Revised International Staging System (R-ISS) 
      score increased survival prediction from an AUC = 0.63 [0.58, 0.69] to an 
      AUC = 0.73 [0.66, 0.78]; p = 0.015. Modelling predictions were confirmed in in 
      vitro tests with PCM cell lines. Our metabolic risk score increases survival 
      prediction accuracy in PCM.
CI  - (c) 2021. The Author(s), under exclusive licence to Springer Nature Limited part of 
      Springer Nature.
FAU - Huang, Han-Ying
AU  - Huang HY
AUID- ORCID: 0000-0002-8635-4867
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
AD  - Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, 
      Guangzhou, P.R. China.
AD  - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, 
      Guangzhou, P.R. China.
FAU - Wang, Yun
AU  - Wang Y
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
AD  - Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, 
      Guangzhou, P.R. China.
FAU - Wang, Wei-da
AU  - Wang WD
AUID- ORCID: 0000-0002-8272-5421
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
AD  - Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, 
      Guangzhou, P.R. China.
FAU - Wei, Xiao-Li
AU  - Wei XL
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, 
      P.R. China.
FAU - Gale, Robert Peter
AU  - Gale RP
AD  - Department of Immunology and Inflammation, Haematology Research Centre, Imperial 
      College London, London, UK.
FAU - Li, Jin-Yuan
AU  - Li JY
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
AD  - Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, 
      Guangzhou, P.R. China.
FAU - Zhang, Qian-Yi
AU  - Zhang QY
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
AD  - Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, 
      Guangzhou, P.R. China.
FAU - Shu, Ling-Ling
AU  - Shu LL
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
AD  - Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, 
      Guangzhou, P.R. China.
FAU - Li, Liang
AU  - Li L
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
AD  - Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, 
      Guangzhou, P.R. China.
FAU - Li, Juan
AU  - Li J
AUID- ORCID: 0000-0002-0909-4731
AD  - Department of Hematology, The First Affiliated Hospital of Sun Yat-sen 
      University, Guangzhou, China. ljuan@mail.sysu.edu.cn.
FAU - Lin, Huan-Xin
AU  - Lin HX
AUID- ORCID: 0000-0002-0621-4486
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China. 
      linhx@sysucc.org.cn.
AD  - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, 
      Guangzhou, P.R. China. linhx@sysucc.org.cn.
FAU - Liang, Yang
AU  - Liang Y
AUID- ORCID: 0000-0002-4226-9580
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China. 
      liangyang@sysucc.org.cn.
AD  - Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, 
      Guangzhou, P.R. China. liangyang@sysucc.org.cn.
LA  - eng
GR  - DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210308
PL  - England
TA  - Leukemia
JT  - Leukemia
JID - 8704895
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Aged
MH  - Antineoplastic Agents/*therapeutic use
MH  - Biomarkers, Tumor/genetics/*metabolism
MH  - Cohort Studies
MH  - Female
MH  - Follow-Up Studies
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Male
MH  - *Metabolome
MH  - Multiple Myeloma/genetics/metabolism/*mortality/pathology
MH  - *Nomograms
MH  - Prognosis
MH  - Survival Rate
EDAT- 2021/03/10 06:00
MHDA- 2021/12/31 06:00
CRDT- 2021/03/09 06:08
PHST- 2020/12/02 00:00 [received]
PHST- 2021/02/18 00:00 [accepted]
PHST- 2021/01/29 00:00 [revised]
PHST- 2021/03/10 06:00 [pubmed]
PHST- 2021/12/31 06:00 [medline]
PHST- 2021/03/09 06:08 [entrez]
AID - 10.1038/s41375-021-01206-4 [pii]
AID - 10.1038/s41375-021-01206-4 [doi]
PST - ppublish
SO  - Leukemia. 2021 Nov;35(11):3212-3222. doi: 10.1038/s41375-021-01206-4. Epub 2021 
      Mar 8.